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Abstract
Background: Human papillomavirus (HPV) infection is a causative factor for cervical cancer. Early detection of high
risk HPV types might help to identify women at high risk of cervical cancer. The aim of the present study was to
examine the HPV prevalence and distribution in cervical smears in a sample of Greek women attending a
gynecological outpatient clinic and to explore the determinants of the infection.
Methods: A total of 225 women were studied. All women underwent a regular gynecological control. 35 HPV
types were studied; 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71,
72, 73, 81, 82, 83, 84, 85 and 89. Also, basic demographic information, sociodemographic characteristics and sexual
behavior were recorded.
Results: HPV was detected in 22.7% of the study population. The percentage of the newly diagnosed women with
HPV infection was 17.3%. HPV-16 was the most common type detected (5.3%) followed by HPV-53 (4.9%). 66.2% of
the study participants had a Pap test during the last year without any abnormalities. HPV infection was related
positively with alcohol consumption (OR: 2.19, 95% CI: 1.04-4.63, P = 0.04) and number of sexual partners (OR: 2.16,
95% CI: 1.44-3.25, P < 0.001), and negatively with age (OR: 0.93, 95% CI: 0.87-0.99, P = 0.03), and monthly income
(OR: 0.63, 95% CI: 0.44-0.89, P = 0.01).
Conclusion: The prevalence of HPV in women attending an outpatient clinic is high. Number of sexual partners
and alcohol consumption were the most significant risk factors for HPV infection, followed by young age and
lower income.
Background
Cervical cancer is the second most common cancer in
women worldwide [1]. Several studies have strongly
implicated human papillomavirus (HPV) infection as a
causative factor in the development of cervical cancer
[2,3]. Based on their association with cervical cancer,
HPV can be grouped to high-risk (such as HPV-16, -18,
-31, and -45) and low-risk HPV types (such as 6, 11, 42,
43, and 44) [4]. High-risk HPV types are present in over
99% of cervical cancers and in the vast majority of cases
of high grade cervical intraepithelial neoplasia [5,6].
Worldwide, approximately, 70% of cervical cancers are
due to HPV types 16 and 18 [3].
Women with normal cervical cytology who are
infected with high risk HPV type have an approximately
100-fold increased risk of developing cervical cancer
compared to uninfected women [7]. Therefore, it has
been suggested that high risk HPV detection might be
used as a tool to identify women at high risk of cervical
cancer, in addition to Pap smears [7,8]. Furthermore,
the development of HPV vaccines and implementation
of vaccination programs might help to reduce the bur-
den of disease [9]. Especially, vaccination against HPV
types 16 and 18 potentially prevents more than two
thirds of cervical cancer cases worldwide. However, the
impact of an HPV vaccination in different geographical
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regions will be related to the prevalence of HPV types
16 and 18 in the different populations [10].
Since, the prevalence of the high risk HPV types varies
among different populations we conducted the present
study in order to examine the HPV prevalence and dis-
tribution in cervical smears in a sample of Greek
women attending a gynecological outpatient clinic and
to explore the determinants of the infection.
Methods
Population
The study population consisted of a consecutive sample
of 225 women attending the gynecological outpatient
clinic of the Maternal and Perinatal Hospital “Elena
Venizelou” between October 2007 and May 2008, for
regular gynecological control. “Elena Venizelou” Hospi-
tal is a tertiary maternal hospital responsible for the
greater region of Athens, the capital of Greece. Pregnant
women or women with a recent delivery were not
enrolled into the study. The refusal rate was low; only 2
women denied taking part into the study.
Basic demographic information, sociodemographic
characteristics, medical history, smoking status, alcohol
consumption and sexual and reproductive behaviour
was obtained at the time of the gynecological visit by a
study nurse. Additional questions were asked on age at
first sex, number of lifetime partners, past history of
sexually transmitted infections, and use of a condom.
Participants were considered as newly diagnosed cases
for HPV infection if they had a negative history for
HPV infection according to their medical records. In
addition, newly diagnosed cases included women who
had never been screened for HPV infection. Subjects
were considered as non-smokers if they have never
smoked or if they had given up smoking for at least
three consecutive years. Heavy drinking was defined as
consuming an average of more than 1 drink per day.
Participants were stratified according to their monthly
income and education level as it is stated at Additional
file 1, Table S1. Females whose monthly incomes did
not exceed 1,000 Euros were considered as low income.
High education level was defined as attending a college
or a university.
All subjects underwent their scheduled examination,
which included the placement of a speculum in the
vagina, visualization of the cervix, and collection of cer-
vical cells using a wooden Ayre spatula and endocervical
brush. After the preparation of a standard cervical
smear, the remaining cells were placed in tubes with
0.9% saline and stored at -20°C prepared for HPV mole-
cular analysis. Pap smears were classified according to
the Bethesda system by local cytopathologists.
The Hospital’s ethical committee provided approval
for this study. All participants gave their written consent
before enrollment to the study. The study was in accor-
dance with the Helsinki declaration.
HPV DNA Detection Techniques
Nucleic acid isolation
The cervical cells removed from the swabs and centri-
fuged in order to be in a pellet form. The supernatant
discarded and the remaining cells were dissolved in 100
μl 1× Phosphate Buffer Saline (PBS). The dissolved cells
transferred to 200 μl Tissue Lysis Buffer and 20 μl Pro-
teinase K according the instruction manual of CLINI-
CAL ARRAY ‘S (HPV) (Biogenomica Spain). The
extracted DNA eluted in 100 μl Elution buffer (Biogen-
omica Spain) and stored in -20°C. The sensitivity and
specificity of the CLINICAL ARRAY’ S HPV kit is
92.3% and 89%, respectively [11].
PCR Amplification
Five microliters (5 μl) of eluted DNA were used in the
PCR amplification of pre alliquoted ready to use vials-
kept at -20°C in alliquots (Biogenomica Spain). The PCR
reaction includes two internal controls in order to avoid
the false negative results from the extraction procedure
and from the PCR inhibitors. The first amplifies a 892
bp fragment of the human CFTR gene and indicates the
DNA existence and the second is a 1202 bp fragment
from a modified plasmid and indicates if there is inhibi-
tors or not.
Hybridization
The PCR product denaturated in 95°C for 15 minutes in
iQ Thermocycler and then thawed in 4°C. Five microli-
ters (5 μl) of the PCR product proceeded in hybridiza-
tion on the specific Array Tubes according the
instruction manual (Biogenomica Spain) on the ATS
Workstation (CLONDIAG Chip Technologies GMBH).
The hybridization results were interpreted by the Speci-
fic CLINICAL ARRAYS Human Papilloma virus soft-
ware program which it has been preinstalled and ready
to use on the ATS Workstation (CLONDIAG Chip
Technologies GMBH).
The following 35 HPV types were studied; 6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54,
56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84,
85 and 89. The oncogenic risk of the HPV types detect-
able with CE marked and IVD marked kit of Genomica
are according to the Munoz et al [12].
A recent meta-analysis examined the association
between detection of HPV DNA and high-grade cervical
intraepithelial neoplasia and invasive cervical cancer,
showing a strong association [13].
Statistical Analysis
Statistical analysis was preformed using programs avail-
able in the SPSS statistical package (SPSS 15.0, Chicago,
USA). All variables were tested for normal distribution
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of the data. Data are shown as mean ± SD, unless it is
stated otherwise. A two sample t-test was used to assess
differences in continuous variables, while a chi-square
test was used for categorical variables. Univariate binary
logistic analysis was performed to look for the relation-
ship between HPV infection and the variables of interest
in the sample population. Then, multivariate analysis
was performed (backward stepwise method) to look for
independent associations between HPV infection and
the variables of interest. All independent variables in the
multivariate analysis were tested for multicolinearity.
P < 0.05 (two-tailed) was considered statistically
significant.
Results
Characteristics of the study population
The characteristics of the study population are sum-
marized in Additional file 1, Table S1. The study popu-
lation consisted of 225 women aged 16 to 45 years
(mean age ± standard deviation: 30.7 ± 6.8 years). Most
of the participating women had high (68.4%) educa-
tional level, were unmarried (52.4%), had their first sex-
ual intercourse before the age of 20 (67.1%), reported a
single regular sexual partner during the last year
(76.4%). Of the married women 19.5% had at least two
full term pregnancies. 55.1% of the participants
reported more than 3 sexual partners during their life-
time, and 29.3% had more than 5 sexual intercourses
monthly. 45.3% of the study participants had high
monthly income.
Condom was the most common contraceptive method
ever used (58.6%). It is noteworthy that almost the one
third of the study participants did not use any contra-
ceptive method (34.2%). Of the study population, 10.6%
had a history of a previous HPV infection and 48% a
history of sexually transmitted disease. 8.0% had never
done a Pap test, while 66.2% had a Pap test during the
last year without any abnormalities. Only one third of
the women were smokers (39.1%), and 48.8% reported
regular alcohol consumption.
Characteristics of women positive for HPV infection
The age of HPV-positive women (n = 51) was (mean
age ± standard deviation) 28.5 ± 6.7 years. Condom was
the most common contraceptive method ever used
(60.8%), while 29.4% did not use any contraceptive
method. Of the HPV-positive women, 23.5% had a his-
tory of a previous HPV infection and 54.9% a history of
sexually transmitted disease. 13.7% had never done a
Pap test, while 58.8% had a Pap test during the last year.
55.0% of the HPV-positive women were smokers and
62.8% reported regular alcohol consumption (Additional
file 1, Table S1).
HPV prevalence and subtypes
HPV was detected in 51 of the 225 women examined
(22.7%) (6 positive for HPV-6, 12 for HPV-16, 2 for
HPV-18, 1 for HPV-31, 2 for HPV-33, 2 for HPV-39, 3
for HPV-51, 8 for HPV-53, 2 for HPV-58, 2 for HPV-
61, 1 for HPV-62, 3 for HPV-66, 3 for HPV-81, 2 for
HPV-83 and 2 for HPV-84). The percentage of the
newly diagnosed women with HPV infection was 17.3%
(39/225). In addition, it must be mentioned that 12
women with a previous history for HPV infection were
found in the HPV negative subsample. These cases were
included in the HPV-negative group for the further
analysis.
16.4% (37/225) of the study population was infected
with a single type and 6.2% (14/225) was infected with
at least two HPV types. In the entire study population,
HPV-16 was the most common type detected (5.3%)
either as a single type or in combination with other
types, followed by HPV-53 (4.9%). It is noteworthy that
the prevalence of oncogenic HPV-18 was low (0.9%).
Oncogenic (HPV 16, 18, 31, 33, 39, 51, 53, 58) and non-
oncogenic (HPV 6, 61, 62, 66, 81, 83, 84) types were
detected in 14.2% and 8.2% of the HPV-positive women,
respectively.
The prevalence of HPV infection among females aged
21 to 30 years was 26.6% whereas the corresponding
prevalence among females aged 16 to 20 years was
57.1%. In detail, the prevalence of HPV-16 and HPV-53
among females aged 21 to 30 years old were 5.5%, 2.8%,
respectively, whereas the corresponding prevalences
among females aged 16 to 20 years were 14.3% and
14.3%, respectively (Figure 1).
Risk factors for HPV infection
The univariate logistic analysis showed significant asso-
ciations between HPV infection and age [odds ratio
(OR): 0.94, 95% Confidence Intervals (95% CI): 0.89-
0.98], monthly income (OR: 0.65, 95% CI: 0.48-0.89),
marital status (OR: 0.37, 95% CI: 0.18-0.73), number of
full term pregnancies (OR: 0.58, 95% CI: 0.36-0.94),
number of sexual partners (OR: 2.17, 95% CI: 1.50-3.15),
smoking status (OR: 1.42, 95% CI: 1.08-1.85), and alco-
hol consumption (OR: 2.27, 95% CI: 1.18-4.35). No any
significant relationships were found between HPV infec-
tion and educational level, nationality, methods of con-
traception, age at first sexual intercourse, and history of
previous HPV infection or other sexual transmitted dis-
eases (Additional file 2, Table S2).
Multivariate analysis demonstrated, after controlling
for smoking, marital status, and number of full term
pregnancies, that HPV infection was related positively
with alcohol consumption (OR: 2.19, 95% CI: 1.04-4.63)
and number of sexual partners (OR: 2.16, 95% CI:
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1.44-3.25), and negatively with age (OR: 0.93, 95% CI:
0.87-0.99) and monthly income (OR: 0.63, 95% CI: 0.44-
0.89) (Additional file 2, Table S2).
Discussion
Prevalence of HPV DNA in a sample of Greek females
aged 16 to 45 years was 22.7%, with the highest preva-
lence (57.1%) among women aged 16 to 20 years.
The percentage of the newly diagnosed women with
HPV infection was 17.3%. Oncogenic HPV types were
detected in 14.2% of the HPV-positive women. The
overall prevalence of high risk HPV-16, HPV-53 and
HPV-18 were 5.3%, 4.9% and 0.9% respectively. Similar
prevalence of HPV-positive women has been reported in
a large sample of US females aged 14 to 59 years
(26.8%) [14]. Other studies in Europe have yielded simi-
lar findings in healthy women [15] as well as women
with history of cervical cancer [16]. A recent study in
our country demonstrated that HPV DNA was positive
in 23.6% of cytologically normal women [17]. Similar
rates have been confirmed by a previous study in malig-
nant biopsies in Greece [18] and even higher rates in
another study in asymptomatic women [19]. However, a
study in healthy women by Agorastos et al. reported
one of the lowest HPV prevalence ever observed inter-
nationally (2.5%) [20]. Also, low prevalence of HPV-
positive women has been reported in studies from Spain
[21] and Vietnam [22].
HPV-16 was the most prevalent oncogenic type either
as a single type or in combination with other types,
while the prevalence of HPV-18 was low. A lot of stu-
dies in different populations have shown that HPV-16
was the most common among the others HPV types
[22-25]. Even higher prevalence of HPV-16 has been
described in different geographic regions ranging from
43.9% in Asia to 72.4% in Africa in women with invasive
cervical cancer [12]. Furthermore, it is known that HPV-
16 represents the most commonly identified HPV type
in low- and high-grade cervical lesions as well as cervi-
cal cancer worldwide [26]. However, a low prevalence of
HPV-16, HPV-53 and HPV-18 has been reported in the
USA [14]. The prevalence of HPV-18 (0.8%) was similar
to that of the present study [14]. On the contrary, stu-
dies from our country using histological samples have
reported higher prevalence of HPV-18 [18,27,28]. A
study by Kroupis et al., in a sample of Greek women
with a history of cervical lesions reported a higher pre-
valence of HPV-53 [17].
Of the total study population, 16.4% was infected with
a single type and 6.2% was infected with at least two
HPV types. The observed prevalence of multiple infec-
tions is low in comparison with the results from studies
from different countries [29-35]. The presence of multi-
ple infections was 0% in Brazil [29], 5.3% in Morocco
[30], 9.8% in Thailand [31], 14.3% in Philippines [32],
16.7% in Paraguay [33], 28% in The Netherlands [34],
and 39% in Costa Rica [35]. In our country a recent
study showed that the prevalence of multiple infections
was 21.2% [17]. These differences in prevalence of mul-
tiple infections could be due to differences in the techni-
que used or real differences in the prevalence of the
HPV types in the populations studied.
The results of the multivariate analysis demonstrated
that HPV infection was related positively with alcohol
consumption and number of sexual partners, and nega-
tively with age and monthly income. A lot of previous
studies have showed that the main risk factor for HPV
infection was the number of sexual partners [36-38].
Also, alcohol consumption was an important risk factor.
A simply explanation is that alcohol consumption might
lead to unsafe sexual behavior and to less adherences to
contraceptive methods. However, the literature data
regarding the potential relationship between alcohol
consumption and HPV infection are conflicting. A pre-
vious study showed that there is a positive relationship
between alcohol and HPV infection [39], while a recent
one showed no relationship [40]. On the contrary, HPV
infection declined with increasing age. Importantly,
other studies also reported the increaased HPV infection
with aging, suggesting the biological effect, such as HPV
immunity acquired over time [35,38,41]. The same pat-
tern was observed in a previous study from our country
[20]. Finally, low monthly income was a significant
determinant of HPV infection. Two studies in the USA
have showed that high-risk HPV infection is common in
poor women [42,43].
Our study has some limitations. As it is mentioned
above, 12 women with a previous HPV infection were
found in the HPV-negative subgroup. This is partially
Figure 1 The prevalence of HPV-16, HPV-18 and HPV-53
according to the age groups (the values are shown as %).
“black square”, HPV-16; “white square”, HPV-18; “grey square”, HPV-53.
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explained by the results of two studies showing that a
single negative HPV test result could lead to missed
HPV infection [44] and that HPV test has low specificity
[45]. In addition, the number of the participants as well
as the age range in our study sample was relatively lim-
ited; only women aged 16-45 years were included.
Therefore, the results of the present study can not be
extrapolated to the total female population of our coun-
try. However, since the outpatient clinic is a referral one
the results of the present study give us important infor-
mation regarding the prevalence of HPV infection
among young and middle aged women.
Conclusions
In conclusion, the prevalence of HPV in women attend-
ing an outpatient clinic is high showing the importance
of the early screening as well as the necessity of preven-
tive measures. The number of sexual partners and alco-
hol consumption were the most significant risk factors
for HPV infection, followed by young age and lower
income. Since, the vaccine against the most prevalent
and high risk HPV subtypes is in use in policies regard-
ing prevention of HPV infection might help to reduce
the risk of infection and cervical cancer. However, larger
epidemiological studies in different regions of our coun-
try are needed in order to report the accurate preva-
lence of HPV infection.
Additional file 1: Table S1. The demographic characteristics of the
study population [the variables are expressed as n (%)].
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2334-10-
27-S1.DOC ]
Additional file 2: Table S2. Univariate and multivariate logistic analysis:
the association between various parameters with HPV infection in the
study population.




1Surgical Department, Naval Hospital of Athens, 70 Dinokratous, 115 21
Athens, Greece. 23rdDepartment of Internal Medicine and Center of
Diabetes, General Hospital of Nikaia “Ag. Panteleimon”, 3 D.Mantouvalou, 184
54 Nikaia, Greece. 3Department of Internal Medicine, “Elena Venizelou”
Hospital, Faculty of Nursing, University of Athens, 2 E.Venizelou, 115 21
Athens, Greece.
Authors’ contributions
All authors participated in the collection, analysis, interpretation of data and
writing of the paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 January 2009
Accepted: 15 February 2010 Published: 15 February 2010
References
1. Pisani P, Bari F, Parkin DM: Estimates of the world-wide prevalence of
cancer for 25 sites in the adult population. Int J Cancer 2002, 97:72-81.
2. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J,
Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human
Papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer
Inst 1995, 87:796-802.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. J Pathol 1999,
189:12-9.
4. Burd EM: Human papillomavirus and cervical cancer. Clinical Microbiology
Reviews 2003, 16:1-17.
5. Franco EL, Schlecht NF, Saslow D: The epidemiology of cervical cancer.
Cancer J 2003, 9:348-59.
6. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L,
Remmink AJ, Risse EK, Linden van der HC, Voorhorst FJ, Kenemans P,
Meijer CJ: Relation of human papillomavirus status to cervical lesions
and consequences for cervical-cancer screening: a prospective study.
Lancet 1999, 354:20-25.
7. Rozendaal L, Walboomers JMM, Linden Van Der JC, Voorhorst FJ,
Kenemans P, Helmerhorst Th JM, Van Ballegooijen M, Meijer CJLM: PCR-
based high-risk HPV test in cervical cancer screening gives objective risk
assessment of women with cytomorphologically normal cervical smears.
Int J Cancer 1996, 68:766-769.
8. Meijer CJLM, Helmerhorst ThJM, Rozendaal L, Linden van der JC,
Voorhorst FJ, Walboomers JMM: HPV typing and testing in gynaecological
pathology: has the time come?. Histopatology 1998, 33:83-86.
9. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ,
Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR:
Safety and immunogenicity trial in adult volunteers of a human
papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001,
93:284-292.
10. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human
papillomavirus types in invasive cervical cancer worldwide: a meta-
analysis. Br J Cancer 2003, 88:63-73.
11. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: Use of
polymerase chain reaction amplification for the detection of genital
human papillomavirus. Cancer Cells 1989, 7:209-214.
12. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV,
Snijders PJ, Meijer CJ, International Agency for Research on Cancer
Multicenter Cervical Cancer Study Group: Epidemiologic classification of
human papillomavirus types associated with cervical cancer. N Engl J
Med 2003, 348:518-527.
13. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS: Persistent
Human Papillomavirus Infection and Cervical Neoplasia: A Systematic
Review and Meta-Analysis. Am J Epidemiol 2008, 168:123-137.
14. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS,
Markowitz LE: Prevalence of HPV infection among females in the United
States. JAMA 2007, 297:813-819.
15. Evander M, Edlund K, Bodén E, Gustafsson A, Jonsson M, Karlsson R,
Rylander E, Wadell G: Comparison of a one-step and a two-step
polymerase chain reaction with degenerate general primers in a
population-based study of human papillomavirus infection in young
Swedish women. Journal of Clinical Microbiology 1992, 30:987-992.
16. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG,
Mielzynska-Lohnas I, Rush BB, Schiffman M: Baseline cytology, human
papillomavirustesting, and risk for cervical neoplasia: a 10-year cohort
analysis. Journal of the National Cancer Institute 2003, 95:46-52.
17. Kroupis C, Thomopoulou G, Papathomas TG, Vourlidis N, Lazaris AC:
Population-based study of human papillomavirus infection and cervical
neoplasia in Athens, Greece. Epidemiol Infect 2007, 135:943-950.
18. Labropoulou V, Diakomanolis E, Dailianas S, Kalpaktsoglou K, Balamotis A,
Mavromara P: Type-specific prevalence of genital human
papillomaviruses in benign, premalignant, and malignant biopsies in
patients from Greece. Sexually Transmitted Diseases 1997, 24:469-474.
19. Agorastos T, Bontis J, Lambropoulos AF, Constantinidis TC, Nasioutzini M,
Tagou C, Katsouyiannopoulos V: Epidemiology of human papillomavirus
infection in Greek asymptomatic women. Eur J Cancer Prev 1995,
4:159-167.
Stamataki et al. BMC Infectious Diseases 2010, 10:27
http://www.biomedcentral.com/1471-2334/10/27
Page 5 of 6
20. Agorastos T, Dinas K, Lloveras B, Bosch FX, Kornegay JR, Bontis JN, de
Sanjose S: Cervical human papillomavirus infection in women attending
gynaecological outpatient clinics in northern Greece. European Journal of
Cancer Prevention 2004, 13:145-147.
21. de Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Muñoz N, Català I,
Meijer CJ, Snijders PJ, Herrero R, Bosch FX: Cervical Human papillomavirus
infection in the female population in Barcelona, Spain. Sex Transm Dis
2003, 30:788-793.
22. Pham TH, Nguyen TH, Herrero R, Vaccarella S, Smith JS, Nguyen Thuy TT,
Nguyen HN, Nguyen BD, Ashley R, Snijders PJ, Meijer CJ, Muñoz N,
Parkin DM, Franceschi S: Human papillomavirus infection among women
in South and North Vietnam. Int J Cancer 2003, 104:213-220.
23. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY,
Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ,
Coursaget P, Franceschi S: Prevalence of human papillomavirus infection
in women in Busan, South Korea. Int J Cancer 2003, 103:413-421.
24. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P,
Hernández P, Salmerón J, Hernández M: Epidemiology of HPV infection
among Mexican women with normal cervical cytology. Int J Cancer 2001,
91:412-420.
25. Matos E, Loria D, Amestoy GM, Herrera L, Prince MA, Moreno J, Krunfly C,
Brule van den AJ, Meijer CJ, Muñoz N, Herrero R, Proyecto Concordia
Collaborative Group: Prevalence of human papillomavirus infection
among women in Concordia, Argentina: a population-based study. Sex
Transm Dis 2003, 30:593-599.
26. Clifford GM, Rana RK, Franceschi S, Smith J, Gough G, Pimenta JM: Human
papillomavirus genotype distribution in low-grade cervical lesions:
comparison by geographic region and with cervical cancer. Cancer
Epidemiol Biomarkers Prev 2005, 14:1157-1164.
27. Dokianakis DN, Papaefthimiou M, Tsiveleka A, Spandidos D: High
prevalence of HPV 18 in correlation with ras gene mutations and
clinicopathological parameters in cervical cancer studied from cervical
cytological smears. Oncol Rep 1999, 66:1327-1331.
28. Vassilandonopoulou G, Panotopoulou E, Fotiou S, Tserkezoglou A,
Machera E, Kottaridis S: Humanpapillomaviruses in cervical cancer I. HPV-
16 and 18 predominate in the Greek population. Anticancer Res 1997,
17:117-120.
29. Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM, Walboomers JMM:
Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer
1994, 69:114-119.
30. Chaouki N, Bosch FX, Muñoz N, Meijer CJLM, Gueddari B, El Ghazi,
Deacon J, Castellsague X, Walboomers JMM: The viral origin of cervical
cancer in Rabat, Morocco. Int J Cancer 1998, 75:546-554.
31. Chichareon S, Herrero R, Muñoz N, Bosch FX, Jacobs MV, Deacon J,
Santamaria M, Chongsuvivatwong V, Meijer CJLM, Walboomers JMM: Risk
factors for cervical cancer in Thailand: a case - control study. J Natl
Cancer Inst 1998, 90:50-57.
32. Ngelangel C, Muñoz N, Bosch FX, Limson GM, Festin MR, Deacon J,
Jacobs MV, Santamaria M, Meijer CJLM, Walboomers JMM: Causes of
cervical cancer in the Philippines: a case - control study. J Natl Cancer
Inst 1998, 90:43-49.
33. Rolon PA, Smith JS, Muñoz N, Klug SJ, Herrero R, Bosch X, Llamosas F,
Meijer CJLM, Walboomers JMM: Human papillomavirus infection and
invasive cervical cancer in Paraguay. Int J Cancer 2000, 85:486-491.
34. Jacobs MV, Walboomers JMM, Snijders PJF, Voorhorst FJ, Daalmeijer NF,
Meijer CJLM: Age-related distribution patterns of 37 mucosotropic HPV
types in women with cytologically normal cervical smears: decreased
high risk/low risk ratio at older age. Int J Cancer 2000, 87:221-227.
35. Herrero R, Hildesheim A, Bratti C, Sherman M, Hutchinson M, Morales J,
Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Schiffman MH:
A population-based study of all grades of cervical neoplasia in rural
Costa Rica. J Natl Cancer Inst 2000, 92:464-473.
36. Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR,
Cadell DM, Kurman RJ, Manos MM: Determinants of genital human
papillomavirus infection in low-risk women in Portland, Oregon. Sex
Transm Dis 1993, 20:274-278.
37. Kjaer SK, Brule van den AJ, Bock JE, Poll PA, Engholm G, Sherman ME,
Walboomers JM, Meijer CJ: Determinants of genital human papillomavirus
(HPV) infection in 1000 randomly chosen young Danish women with
normal PAP smear: are there different risk profiles for oncogenic and
non oncogenic HPV types?. Cancer Epidemiol Biomarkers Prev 1997,
6:799-805.
38. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA,
Landesman SH: Declining prevalence of cervicovaginal human
papillomavirus infection with age is independent of other risk factors.
Sex Transm Dis 1996, 23:333-341.
39. Sikström B, Hellberg D, Nilsson S, Mårdh PA: Smoking, alcohol, sexual
behaviour and drug use in women with cervical human papillomavirus
infection. Arch Gynecol Obstet 1995, 256:131-137.
40. Tolstrup J, Munk C, Thomsen BL, Svare E, Brule van den AJ, Grønbaek M,
Meijer C, Kjaer Krüger S: The role of smoking and alcohol intake in the
development of high-grade squamous intraepithelial lesions among
high-risk HPV-positive women. Acta Obstet Gynecol Scand 2006,
85:1114-1119.
41. Syrjänen S, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T,
Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I,
Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L,
Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A,
Juschenko A, Tosi P, Cintorino M, Santopietro R, Syrjänen K: Acquisition of
high-risk human papillomavirus infections and pap smear abnormalities
among women in the new independent states of the Former Soviet
Union. Journal of Clinical Microbiology 2004, 42:505-511.
42. Kahn JA, Lan D, Kahn RS: Sociodemographic factors associated with high-
risk human papillomavirus infection. Obstet Gynecol 2007, 110:87-95.
43. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG,
Studentsov YY, McAdams M, Schiffman M: A case-control study of risk
factors for invasive cervical cancer among U.S. women exposed to
oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers
Prev 2004, 13:1574-1582.
44. Peevor R, Bowden S, Jones J, Fiander AN, Hibbitts S: Human Papillomavirus
negative but dyskaryotic cervical cytology: re-analysis of molecular
testing. J Clin Virol 2009, 44:322-324.
45. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM,
Koutsky LA: Evaluation of human papillomavirus testing in primary
screening for cervical abnormalities: comparison of sensitivity,
specificity, and frequency of referral. JAMA 2002, 288:1749-1757.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2334/10/27/prepub
doi:10.1186/1471-2334-10-27
Cite this article as: Stamataki et al.: Prevalence of HPV infection among
Greek women attending a gynecological outpatient clinic. BMC Infectious
Diseases 2010 10:27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stamataki et al. BMC Infectious Diseases 2010, 10:27
http://www.biomedcentral.com/1471-2334/10/27
Page 6 of 6
